J Korean Radiol Soc.  1986 Aug;22(4):490-494. 10.3348/jkrs.1986.22.4.490.

Clinical use of lipiodol in hepatic arteriography

Abstract

Lipiodol, lipid soluble contrast media, was applied to 59 patients, who was clinically suspected to havehepatic tumor, in the department of Diagnotic Radiology, Seoul National University Hospital. The results of theclinical use of Lipiodol were as follows: 1. The clinical diagnosis was hepatocellular carcinoma(HCC) in 50 cases,cavernous hemangioma in 4 cases, metastasis in one case and others in 4 cases. 2. After hepatic arteriography,Lipiodol only was injected in 28 cases, mixture of Lipiodol and Mitomycin was injected in 22 cases andtranscatheter arterial embolization was performed additionally after injection of Lipiodol and Mitomycin in 9cases. 3. Among the 50 cases of HCC, Lipiodol was accumulated in the lesion in 49 cases. However, similaraccumulation of Lipiodol occured in a metastatic cancer and cavernous hemangiomas. 4. Plain radiographic patternsof Lipiodol accumulation could be divided into fine granular type, nodular type and linear or branching type. Thelinear or branching pattern disappeared in follow-up radiography after one week. 5. As minor complication afterLipiodol Injection. GOY &GPT were transiently elevated in 30 cases and normalized in a week. Abdominal pain andfever developed but subsided in a week too. 6. When an appropriate lipid-soluble chemotherapeutic agent orradioisotope is applied to this phenomenon in which Lipiodol is selectively accumulated in hepatic tumor, thediagnostic and therapeutic values will be more enhanced.


MeSH Terms

Abdominal Pain
Angiography*
Contrast Media
Diagnosis
Ethiodized Oil*
Follow-Up Studies
Hemangioma
Hemangioma, Cavernous
Humans
Mitomycin
Neoplasm Metastasis
Radiography
Seoul
Contrast Media
Ethiodized Oil
Mitomycin
Full Text Links
  • JKRS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr